MX2020004724A - Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. - Google Patents

Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Info

Publication number
MX2020004724A
MX2020004724A MX2020004724A MX2020004724A MX2020004724A MX 2020004724 A MX2020004724 A MX 2020004724A MX 2020004724 A MX2020004724 A MX 2020004724A MX 2020004724 A MX2020004724 A MX 2020004724A MX 2020004724 A MX2020004724 A MX 2020004724A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
disorders associated
methods
esterase inhibitor
Prior art date
Application number
MX2020004724A
Other languages
English (en)
Other versions
MX389449B (es
Inventor
Mark Cornell Manning
Cynthia Gallagher
Steven Ruddy
Original Assignee
Viropharma Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020004724(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viropharma Biologics Llc filed Critical Viropharma Biologics Llc
Publication of MX2020004724A publication Critical patent/MX2020004724A/es
Publication of MX389449B publication Critical patent/MX389449B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones para el tratamiento y/o prevención de trastornos asociados con la deficiencia del inhibidor de C1 esterasa.
MX2020004724A 2013-03-15 2014-03-17 Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. MX389449B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15
PCT/US2014/030309 WO2014145519A2 (en) 2013-03-15 2014-03-17 C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency

Publications (2)

Publication Number Publication Date
MX2020004724A true MX2020004724A (es) 2022-01-18
MX389449B MX389449B (es) 2025-03-20

Family

ID=51538486

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020004724A MX389449B (es) 2013-03-15 2014-03-17 Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2015011281A MX373965B (es) 2013-03-15 2014-03-17 Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
MX2021011946A MX2021011946A (es) 2013-03-15 2015-08-28 Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2015011281A MX373965B (es) 2013-03-15 2014-03-17 Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
MX2021011946A MX2021011946A (es) 2013-03-15 2015-08-28 Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.

Country Status (30)

Country Link
US (9) US9616111B2 (es)
EP (3) EP3290046B1 (es)
JP (9) JP6184581B2 (es)
KR (4) KR20150135242A (es)
CN (2) CN111529708A (es)
AU (3) AU2014232912A1 (es)
BR (1) BR112015023207A8 (es)
CA (2) CA3054718A1 (es)
CY (2) CY1119419T1 (es)
DE (1) DE202014011208U1 (es)
DK (2) DK3290046T3 (es)
EA (1) EA201591278A1 (es)
ES (2) ES2639833T3 (es)
GB (1) GB2530921B (es)
HK (1) HK1250912B (es)
HR (2) HRP20171269T1 (es)
HU (2) HUE041837T2 (es)
IL (2) IL241549B (es)
LT (2) LT2968434T (es)
ME (2) ME03326B (es)
MX (3) MX389449B (es)
PL (2) PL3290046T3 (es)
PT (2) PT2968434T (es)
RS (2) RS58351B1 (es)
SG (2) SG10201707598QA (es)
SI (2) SI2968434T1 (es)
SM (2) SMT201900141T1 (es)
TR (1) TR201900319T4 (es)
WO (1) WO2014145519A2 (es)
ZA (3) ZA201507604B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03326B (me) 2013-03-15 2019-10-20 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
ES2708655T3 (es) 2013-11-22 2019-04-10 Shire Viropharma Inc Métodos para tratar el rechazo mediado por anticuerpos en pacientes con trasplante de órganos con el inhibidor de la c1-esterasa
JP6516855B2 (ja) * 2015-02-20 2019-05-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤の医薬製剤
CN108025047B (zh) * 2015-05-28 2021-11-19 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
WO2017087882A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
JP2019534240A (ja) * 2016-08-23 2019-11-28 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US20200390872A1 (en) 2018-02-28 2020-12-17 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
WO2019245038A1 (ja) 2018-06-22 2019-12-26 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
TWI854983B (zh) 2018-06-22 2024-09-11 日商順天生化股份有限公司 誘導免疫耐受之抗體、被誘導之淋巴球、及使用被誘導之淋巴球之細胞治療劑治療方法
TWI832868B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 用於誘發感染性免疫耐受之組合物
JP7718272B2 (ja) * 2019-12-16 2025-08-05 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
CN117120076A (zh) * 2021-01-27 2023-11-24 斯帕克治疗公司 用于治疗遗传性血管性水肿的组合物和方法
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE69429816T2 (de) * 1993-09-01 2002-09-19 Stichting Sanquin Bloedvoorziening, Amsterdam C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
AU1042597A (en) 1995-12-18 1997-07-14 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DK1252184T3 (da) 2000-01-31 2008-02-04 Pharming Intellectual Pty Bv Human C1-inhibitor produceret i mælk af transgene dyr
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
PT1626736T (pt) 2003-05-16 2020-10-13 Pharming Intellectual Property B V Inibidor c1 com curta meia-vida para tratamento transitório
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
CA2654440C (en) 2005-06-06 2013-09-03 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
MX2008004693A (es) 2005-10-21 2008-09-03 Catalyst Biosciences Inc Proteasas modificadas que inhiben la activacion del complemento.
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
DK1965831T3 (da) * 2005-12-21 2011-10-24 Pharming Intellectual Pty Bv Anvendelse af C1-inhibitor til forebyggelse af iskæmi-reperfusionsskade
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
AU2010306581B2 (en) 2009-10-16 2015-03-19 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
US9815876B2 (en) 2010-03-05 2017-11-14 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
AU2012311483B2 (en) 2011-09-24 2016-03-10 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-inhibitor
CN104080474B (zh) * 2011-12-22 2016-04-27 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
CA2867611A1 (en) 2012-03-16 2013-09-19 Belrose Pharma, Inc. Polymeric conjugates of c1-inhibitors
CA2902841A1 (en) 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
ME03326B (me) * 2013-03-15 2019-10-20 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム

Also Published As

Publication number Publication date
ZA201706929B (en) 2019-05-29
WO2014145519A2 (en) 2014-09-18
CN111529708A (zh) 2020-08-14
JP6877471B2 (ja) 2021-05-26
KR20150135242A (ko) 2015-12-02
RS58351B1 (sr) 2019-03-29
HRP20171269T1 (hr) 2017-11-03
ES2713004T3 (es) 2019-05-17
GB2530921B (en) 2017-09-20
SMT201900141T1 (it) 2019-05-10
SI2968434T1 (sl) 2017-11-30
US20200261556A1 (en) 2020-08-20
HRP20190270T1 (hr) 2019-04-05
JP2019073545A (ja) 2019-05-16
DK3290046T3 (en) 2019-03-18
DK2968434T3 (en) 2017-09-11
MX2015011281A (es) 2016-03-03
KR102430453B1 (ko) 2022-08-05
US20180153972A1 (en) 2018-06-07
EP2968434B1 (en) 2017-06-28
MX373965B (es) 2020-07-13
ES2639833T3 (es) 2017-10-30
PL3290046T3 (pl) 2019-05-31
CY1121653T1 (el) 2020-07-31
KR20220070049A (ko) 2022-05-27
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
PL2968434T3 (pl) 2018-01-31
JP2018119002A (ja) 2018-08-02
BR112015023207A2 (pt) 2017-11-21
AU2020203183A1 (en) 2020-06-04
AU2014232912A1 (en) 2015-09-03
JP2018119000A (ja) 2018-08-02
HK1220403A1 (en) 2017-05-05
US20170224788A1 (en) 2017-08-10
US20180085441A1 (en) 2018-03-29
US20190160157A1 (en) 2019-05-30
DE202014011208U1 (de) 2018-08-23
CA2904543A1 (en) 2014-09-18
CY1119419T1 (el) 2018-03-07
MX2021011946A (es) 2021-11-17
EP2968434A2 (en) 2016-01-20
SG11201507616VA (en) 2015-10-29
PT2968434T (pt) 2017-09-18
ME02865B (me) 2018-04-20
EP2968434A4 (en) 2016-03-02
CA2904543C (en) 2019-10-08
CN105517559A (zh) 2016-04-20
US20180110844A1 (en) 2018-04-26
PT3290046T (pt) 2019-02-18
KR20210021146A (ko) 2021-02-24
US9616111B2 (en) 2017-04-11
US10080788B2 (en) 2018-09-25
SMT201700415T1 (it) 2017-11-15
LT3290046T (lt) 2019-03-12
US10105423B2 (en) 2018-10-23
GB2530921A (en) 2016-04-06
US20160015795A1 (en) 2016-01-21
BR112015023207A8 (pt) 2018-01-23
AU2020203183B2 (en) 2022-06-02
AU2018229558A1 (en) 2018-10-04
JP2016516073A (ja) 2016-06-02
AU2018229558B2 (en) 2020-03-05
HK1250912B (en) 2020-01-10
JP2019073546A (ja) 2019-05-16
ME03326B (me) 2019-10-20
JP6473536B2 (ja) 2019-02-20
JP6877470B2 (ja) 2021-05-26
HUE041837T2 (hu) 2019-05-28
EA201591278A1 (ru) 2016-03-31
KR102579789B1 (ko) 2023-09-15
CA3054718A1 (en) 2014-09-18
US20190160158A1 (en) 2019-05-30
TR201900319T4 (tr) 2019-02-21
JP6184581B2 (ja) 2017-08-23
JP2019073544A (ja) 2019-05-16
JP6473534B2 (ja) 2019-02-20
JP6422520B2 (ja) 2018-11-14
JP2018119001A (ja) 2018-08-02
ZA201507604B (en) 2018-05-30
US11534482B2 (en) 2022-12-27
JP6877472B2 (ja) 2021-05-26
IL276153A (en) 2020-09-30
JP2021088599A (ja) 2021-06-10
LT2968434T (lt) 2017-09-25
IL241549B (en) 2020-08-31
JP2017105847A (ja) 2017-06-15
JP6473535B2 (ja) 2019-02-20
MX389449B (es) 2025-03-20
HUE036224T2 (hu) 2018-06-28
EP3290046A1 (en) 2018-03-07
ZA201806793B (en) 2020-01-29
EP3290046B1 (en) 2019-01-02
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
IL276153B (en) 2022-06-01
WO2014145519A3 (en) 2014-12-31
KR20210129267A (ko) 2021-10-27
US11364288B2 (en) 2022-06-21
GB201519921D0 (en) 2015-12-23
NZ751555A (en) 2021-07-30
SI3290046T1 (sl) 2019-04-30
SG10201707598QA (en) 2017-10-30
EP3508213A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017025004A2 (pt) composições compreendendo cepas bacterianas
BR112019012062A2 (pt) tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos
MX2016015724A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
CR20170500A (es) Compuestos heterocíclicos como inhibidores de lsd1
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
BR112018003493A2 (pt) variantes de quimosina com propriedades aperfeiçoadas
BR112018001451A2 (pt) compostos úteis para a inibição de ror-gama-t
BR112017025263A2 (pt) método para o tratamento de doença neurológica
GB2557753A (en) Substituted aminoalkylazoles as malarial aspartic protease inhibitors
UY36306A (es) Sintesis de ent-progesterona e intermediarios de la misma
BR112016019395A2 (pt) composição
BR112017027536A2 (pt) variantes da quimosina com propriedades aperfeiçoadas
BR112018007290A2 (pt) minha patente 1